Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 |
| clinicaltrials |
| NCT02989064 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | completed | Phase 1 | 10 | AdaptimmuneINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06086665 | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer(REFIRM) | completed | — | 850 | Asan Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03535831 | PSMA PET Registry (18F-DCFPyL)(PM-PPR) | completed | N/A | 142 | University Health Network, TorontoOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT05701007 | Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | completed | — | 1,083 | PfizerINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05011799 | The Peer Genetic Study | completed | N/A | 149 | Thomas Jefferson UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT00625755 | A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03622385 | Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer | completed | — | 10 | Baylor Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04701918 | Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03503344 | Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer(PILLAR) | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT06840548 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer(OncoCAIX) | completed | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04870515 | Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06839378 | Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei | completed | N/A | 36 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04553939 | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | completed | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04601129 | Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery(RREIN) | completed | — | 60 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT03027479 | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss(METERMUS-IMC) | completed | N/A | 70 | University Hospital, ToursOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02600156 | Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors | completed | N/A | 7 | Mayo ClinicOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04566029 | Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas(AMI) | completed | — | 40 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04501913 | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes | completed | — | 22 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05579847 | Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06870539 | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment | completed | — | 49 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03575013 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | completed | Phase 1 | 21 | Yousef ZakhariaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)(KEYNOTE-B61) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Dec 3, 2025 | clinicaltrials |
| NCT04447703 | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | completed | N/A | 346 | Thomas Jefferson UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04543903 | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer | completed | N/A | 1 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05630131 | ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy | completed | — | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06128525 | Prostate Resection After Microwave Ablation (PRAMA) | completed | N/A | 1 | University of Southern CaliforniaOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07232927 | Evaluation of Hemostatic Agents in Partial Nephrectomy(HEMOSTA-PN) | completed | N/A | 150 | Ankara UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | completed | — | 327 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT03860961 | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | completed | N/A | 550 | NRG OncologyOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials